drug · gene
voretigene neparvovec
Phase 2updated 6mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 2community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
targets
Retinoid isomerohydrolase
all catalysts(0)
nothing on the calendar yet
Trials studying voretigene neparvovec
- —A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
- phase2Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
- phase3Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
- phase3Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
News(3)
- Emerging biotech hubs step up as innovation economics evolveHow India and other emerging hubs for drug development can be key to reshaping medical costs globally.biospace · 9h ago
- Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patientsAfter Novartis confirmed the reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy, the FDA will determine if any regulatory action is needed for Zolgens…biospace · 6d ago
- Novartis confirms 9 reported cases of tumors in patients treated with ZolgensmaAdvocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of tumors in patients who have been treated with the spinal muscular atrophy gen…biospace · 10d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that